文献速递药物相互作用

中重度特应性皮炎患者接受度普利尤单抗治疗时潜在疾病介导的药物相互作用评估

Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
PubMed 文献 · Clin Pharmacol Ther · 2018-04-02

这项开放标签药物相互作用研究在14例中重度特应性皮炎患者中,评估度普利尤单抗阻断IL-4和IL-13信号对CYP450酶代谢药物药代动力学的影响。患者在度普利尤单抗治疗前和治疗28天后分别口服五种CYP450底物,结果显示度普利尤单抗对CYP450底物的药代动力学无临床相关影响,并提供显著临床获益且总体耐受良好。

要点

  • 度普利尤单抗对CYP450底物药代动力学无临床相关影响。
  • 度普利尤单抗提供显著临床获益且总体耐受良好。
  • 仅报告1例严重不良事件,为全身炎症反应综合征,停药后缓解。

核心结论

  • 在2型炎症患者中阻断IL-4/IL-13信号似乎不显著影响CYP450酶活性,度普利尤单抗 unlikely 影响CYP450底物的药代动力学。

研究设计与样本

  • 开放标签药物相互作用研究,纳入14例中重度特应性皮炎患者。
  • 在度普利尤单抗治疗开始前和开始后28天评估五种口服CYP450底物的药代动力学。
  • 度普利尤单抗给药方案为皮下300 mg每周一次。

主要发现

  • 度普利尤单抗对CYP450底物的药代动力学无临床相关影响。
  • 度普利尤单抗提供显著临床获益且总体耐受良好。
  • 仅报告1例严重不良事件,为全身炎症反应综合征,停药后缓解。

关键数值与推荐

  • 五种CYP450底物及其代谢酶:咪达唑仑(CYP3A)、奥美拉唑(CYP2C19)、S-华法林(CYP2C9)、咖啡因(CYP1A2)、美托洛尔(CYP2D6)。
  • 度普利尤单抗皮下300 mg每周一次。

临床怎么用

  • 特应性皮炎患者使用度普利尤单抗时,预计不会对经CYP450代谢的合并用药药代动力学产生临床相关影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This open-label drug-drug interaction study assessed whether blockade by dupilumab of interleukin (IL)-4 and IL-13 signaling affects the pharmacokinetics of drugs metabolized by cytochrome P450 (CYP450) enzymes. The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300 mg weekly) in 14 patients with moderate-to-severe atopic dermatitis. Dupilumab had no clinically relevant effects on the pharmacokinetics of CYP450 substrates, provided substantial clinical benefit, and was generally well tolerated. Only one serious adverse event was reported, an episode of systemic inflammatory response syndrome that resolved after treatment was discontinued. In summary, blockade of IL-4/IL-13 signaling in patients with type 2 inflammation does not appear to significantly affect CYP450 enzyme activities; the use of dupilumab in atopic dermatitis patients is unlikely to influence the pharmacokinetics of CYP450 substrates.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Davis JD, Bansal A, Hassman D, et al. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab. Clin Pharmacol Ther. 2018. PMID: 29498038. doi:10.1002/cpt.1058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。